Impact of Psychomotor Therapy on the Quality of Life in Depression

Difference in quality of life assessed using the Short-Form 36 Health Survey

The effectiveness of psychomotor therapy in improving clinical outcomes or quality of life
 for individuals with depression is unclear.
 
 The investigators will assess how the participants' quality of life and psychomotor profile
 change over time.
 
 The study aims to compare the quality of life at 3 months between patients who received 3
 months of personalised psychomotor therapy in addition to standard treatment and those who
 received standard treatment alone.
 
 The study lasted for 6 months, and the investigators expects a total of 128 people to
 participate in this research across several hospital establishments. This study evaluates the
 effectiveness of two types of treatment, divided into two randomly selected groups.
 
 To participate, individuals must have a medical diagnosis of major depressive disorder (MDD)
 and be between the ages of 20 and 60.
 
 They must have depressive symptoms with an HDRS score greater than 16 and provide informed
 consent. They must be treated or hospitalised at the Centre Hospitalier Esquirol or the
 Centre Hospitalier Henri Laborit (France).
 
 After providing consent, they will undergo an initial clinical interview that evaluates
 anxiety, self-esteem, pleasure, and quality of life. The therapist assessed the participant's
 muscle tone, gross motor skills, praxis, manual dexterity, rhythm, processing of sensory
 information, and body image.
 
 Following the assessment, the participant was randomly assigned to either the experimental or
 control group.
 
 The experimental group received the usual treatment for depression and underwent psychomotor
 therapy once a week for 12 weeks.
 
 The control group received the standard treatment for depression and underwent weekly
 telephone interviews.
 
 An assessment is scheduled at 1 month to evaluate the participant's health status, including
 any changes to treatment and assessment of anxiety and depressive symptoms.
 
 Another interim check-up is scheduled at 3 months to assess the patient's health status. The
 interview will also assess any changes to treatment, anxiety and depressive symptoms, quality
 of life, and psychomotor function.
 
 A final visit will be scheduled at 6 months for an assessment of the participant's health.
 The interview will also assess any changes to treatment, anxiety and depressive symptoms,
 quality of life, and psychomotor function.